<DOC>
	<DOCNO>NCT02916095</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics Kanitinib determine optimal dose patient recurrent metastatic solid tumor .</brief_summary>
	<brief_title>Kanitinib Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Evaluation recurrent metastatic solid tumor patient Kanitinib single dose continuous multiple dose safety tolerability , determine maximum tolerated Connie imatinib dose ( MTD ) phase II trial recommend dosage .</detailed_description>
	<criteria>18 year 65 year old , gender patient ( recruit doseescalation stage doseexpansion stage ) recurrent metastatic solid tumor confirm histology staining . medullary thyroid carcinoma , radioactive iodine resistant differentiate thyroid cancer , renal cell carcinoma , lung cancer , liver cancer , gastric cancer prostate cancer priority selection . Patients response standard therapy able tolerate standard therapy . Have measurable tumor lesion ( evaluate RECIST1.1 criterion . ) Vital organ without seriously abnormality With Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Expected survival time estimate least 12 week Competent comprehend , sign , date approve informed consent form Absolute neutrophil count ( ANC ) &lt; 1.5 x 109 / L platelet &lt; 100 x 109 / L hemoglobin &lt; 9 g/dL ( refer normal reference range clinical trial center ) . Total bilirubin &gt; 1.5×the upper limit normal range ( ULN ) . Aspartate aminotransferase （AST）and/or Alanine transaminase（ALT）and/or Alkaline phosphatase ( ALP ) ＞1.5xULN without liver metastasis ; AST and/or ALT and/or ALP level ≥5xULN liver metastasis . Serum creatinine ＞1.5xULN . The porthrombin international normalize ratio ( INR ) activate partial thromboplastin time ( aPPT ) ＞1.5xULN Receive chemotherapy ( within 2 week short halftime TKIs reagent ) , hormonal therapy , radiation therapy , biologics therapy immunotherapy ( within 6 week nitrosoureas mitomycin ) 4 week prior enrolment , except : Gonadotrophin release hormone ( GnRH ) therapy prostate cancer Hormonereplacement therapy oral contraceptive Adverse event prior anticancer therapy resolve Grade ≤ 1 , except alopecia . Brain metastasis spinal cord compression definitively treat surgery and/or radiation therapy , Brain metastases spinal cord compression receive treatment without image evidence show stability ≥ 14 day . prior presence malignancy , exception previously treat stage I B low grade cervical cancer， noninvasive basal cell squamous cell cancer , breast cancer complete remission ( CR ) &gt; 10 year , melanoma CR &gt; 10 year malignant tumor CR &gt; 5 year . Any following gastrointestinal disease : Active gastric duodenal ulcer intestinal obstruction ; History abdominal fistula , gastrointestinal perforation abdominal abscess , active digestive tract bleeding . Presence hemorrhage ( hemoptysis ) thrombosis disease，or currently receive treatment warfarin , aspirin , low molecular weight heparin ( LMWH ) , antiplatelet drug ( low dose mention drug prophylaxis allow ) History nephrotic syndrome . Patients active infection , mental disorder serious nonmalignant disease , congestive heart failure unstable angina within 3 month prior study entry , myocardial infarction stroke within six month prior study entry , serious arrhythmia ; receive therapeutical dose antihypertension drug systolic blood pressure ≥160 mmHg diastolic blood pressure≥100 mmHg （measured least twice） . Receive surgery ( include minimally invasive biopsy , open biopsy major injury ) within 30 day , unhealed surgical incision , ulcer , fracture , tooth extraction dental surgery open wound . Inability take oral medication , prior surgical procedure serious gastrointestinal disorder dysphagia disease may affect drug absorption opinion investigator . With clinical significance liver disease history , include viral hepatitis , cirrhosis . Known human immunodeficiency virus infection . Pregnant lactating woman take contraceptive , include men . Inability comply study followup procedure Involved clinical trial &lt; 30 day prior enrollment . Any disease , metabolic dysfunction , abnormal physical examination finding , clinical laboratory finding . According investigator ' judgment , patient certain disease condition suitable use study drug , affect interpretation result study , high risk patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>